Eurofins Pharma Discovery Services
Eurofins Pharma Discovery Services has supported Drug Discovery research for >40 years. We are recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling.
In addition to our strengths with in vitro safety pharmacology, we also offer a broad portfolio of over 3500 drug discovery services and 1800 products, including; in vitro assays, cell-based phenotypic assays, safety pharmacology & efficacy, ADME Tox, chemistry and custom proteins and assay development capabilities for a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes.
The scientific and operational expertise provided by our Eurofins Pharma Discovery Services global teams contributes insights and added value to our clients' drug discovery programs. Our teams have broad drug discovery capabilities, expertise and proven experience in meeting a wide variety of project objectives successfully with respect to the delivery of quality data and on-time performance. We have robust, efficient processes and quality systems in place for handling a variety of types and volumes of samples and on-time delivery of reports.
Our broad global service capabilities, and decades of experience in providing drug discovery services, result in the delivery of high quality, reproducible study performance with few repeats and high client satisfaction. The Eurofins Pharma Discovery Services capabilities, expertise, knowledge and skill sets enable us to provide our clients the additional benefit of being able to work with a single outsourcing provider (CRO) for their drug discovery programs.
The Eurofins Pharma Discovery Services team was built by bringing together the market leading drug discovery expertise of Panlabs (acquired in 2012 from Ricerca), Cerep (acquired in 2013), EMD Millipore's Discovery & Development Solutions business (acquired from Merck KGaA in 2014), Villapharma Research (acquired in 2017) and DiscoverX (acquired in 2017). With over 500 people in nine operational sites worldwide our global team offers the high quality, reliable solutions and support our clients depend on to advance their drug discovery programs
Combining our broad, high quality, industry leading drug discovery products & services portfolios together enables us to support our global clients with one of the industry’s largest and broadest portfolios.
To learn more about the Eurofins Pharma Discovery Services capabilities, visit our new integrated website and eCommerce system at www.eurofinsdiscoveryservices.com